COVID-19 and cancer comorbidity: therapeutic opportunities and challenges (Russian translation)

Автор: Pathania A.S., Prathipati P., Abdul B.A.A., Chava S., Katta S.S., Gupta S.C., Gangula P.R., Pandey M.K., Durden D.L., Byrareddy S.N., Challagundla K.B.

Журнал: Juvenis scientia @jscientia

Рубрика: Переводные статьи

Статья в выпуске: 6 т.7, 2021 года.

Бесплатный доступ

The coronavirus disease 2019 (COVID-19) is a viral disease caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that affects the respiratory system of infected individuals. COVID-19 spreads between humans through respiratory droplets produced when an infected person coughs or sneezes. The COVID-19 outbreak originated in Wuhan, China at the end of 2019. As of 29 Sept 2020, over 235 countries, areas or territories across the globe reported a total of 33,441,919 confirmed cases, and 1,003,497 confirmed deaths due to COVID-19. Individuals of all ages are at risk for infection, but in most cases disease severity is associated with age and pre-existing diseases that compromise immunity, like cancer. Numerous reports suggest that people with cancer can be at higher risk of severe illness and related deaths from COVID-19. Therefore, managing cancer care under this pandemic is challenging and requires a collaborative multidisciplinary approach for optimal care of cancer patients in hospital settings. In this comprehensive review, we discuss the impact of the COVID-19 pandemic on cancer patients, their care, and treatment. Further, this review covers the SARS-CoV-2 pandemic, genome characterization, COVID-19 pathophysiology, and associated signaling pathways in cancer, and the choice of anticancer agents as repurposed drugs for treating COVID-19.

Еще

Covid-19, coronaviruses, sars-cov-2, cancer, inflammation, comorbidity

Короткий адрес: https://sciup.org/14123689

IDR: 14123689   |   DOI: 10.32415/jscientia_2021_7_6_28-70

Статья обзорная